Venus bags Mexican patent for antobiotic Vancoplus
Venus Remedies Limited, a leading research based global pharmaceutical company has received its first patent from Mexico for "Vancoplus", a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus ( MRSA ) infections.
The patent has been granted from the Mexico Patent office and is valid till February 2026.
Speaking on this achievement, Dr. Manu Chaudhary, Joint Managing Director and Director-Research, Venus Remedies Limited said, "Receiving a patent grant from Mexico for our research product Vancoplus at this point in time when the frequency of MRSA strains is growing high (50-85pc ) in Mexico is a great achievement for us."
"Vancoplus will prove to be the best known remedy to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria in a situation wherein around 3 to 6 percent of the population carries the community form of MRSA."
As per the CDC reports published in the Journal of the American Medical Association in 2010, MRSA infections are constantly on the rise in the community and resistance against antibiotics with nearly 48pc of S. aureus isolates were resistant to oxacillin (MRSA), and 49pc were resistant to levofloxacin; 33pc of Enterococcus faecium isolates were resistant to vancomycin and so on.
Chaudhary said, "With the present scenario in mind, our novel product 'Vancoplus' can prove to be a life saving solution in Mexico to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria which causes meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin structure infections and staphylococcal endocarditis."
Talking on the business side, Dheeraj Aggarwal, CFO, Venus Remedies Limited said, "The value of the pharmaceutical markets in Latin America is at USD 50 billion, growing at the CAGR of approximately 15- 20pc . Mexico being the second leading market in the region represents a growing consumer base for the drug industry as by 2020 the regional population may be as high as 687 million."
Venus Remedies is currently exporting to the various countries of LAC such as Columbia, Peru, Guatemala, Dominican Republic, Jamaica, Bahamas and the Caribbean.
Its export to LAC has been growing at a rate of near 100pc in the past 3 years and LAC is contributing around 15pc of the total exports.
He further added that receiving a patent grant from Mexico is definitely going to give a boost to our export in the region as we have already filed for market authorisation in various countries such as Mexico and few more countries in LAC.
Vancoplus has the potential to restrict transfer of bacterial resistance from MRSA to other strains by preventing conjugation and transfer of plasmids containing resistant genes.
It is also the only known therapeutic option for breaking of bacterial biofilm formed by gram positive bacteria, one of the most common causes of bacterial resistance, said the drug maker.
The total market size of MRSA in the world accounts for USD 9 billion.
At present it is growing at CAGR of 4.8 per cent which is estimated to reach to USD 12.4 billion by 2017.
Venus expects to grab a fair share of this market within 3 years of launch of its novel research product in all major territories of the world.